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Cannabinoids are considered as key mediators in the pathophysiology of inﬂammatory diseases, including atherosclerosis. In
particular, they have been shown to reduce the ischemic injury after acute cardiovascular events, such as acute myocardial
infarction and ischemic stroke. These protective and anti-inﬂammatory properties on peripheral tissues and circulating
inﬂammatory have been demonstrated to involve their binding with both selective cannabinoid type 1 (CB1) and type 2 (CB2)
transmembrane receptors. On the other hands, the recent discoveries of novel diﬀerent classes of cannabinoids and receptors have
increased the complexity of this system in atherosclerosis. Although only preliminary data have been reported on the activities
of novel cannabinoid receptors, several studies have already investigated the role of CB1 and CB2 receptors in ischemic stroke.
While CB1 receptor activation has been shown to directly reduce atherosclerotic plaque inﬂammation, controversial data have
been shown on neurotransmission and neuroprotection after stroke. Given its potent anti-inﬂammatory activities on circulating
leukocytes, the CB2 activation has been proven to produce protective eﬀects against acute poststroke inﬂammation. In this paper,
we will update evidence on diﬀerent cannabinoid-triggered avenues to reduce inﬂammation and neuronal injury in acute ischemic
stroke.
1.Introduction
Ischemic stroke has become one of the leading causes of
mortality and severe disability in several countries, including
developing nations [1, 2]. It is provoked by an acute,
complete, and prolonged interruption of the arterial ﬂow
in the brain characterized by residual tissue infarction [3].
Although extensive studies have been performed to investi-
gate the role of diﬀerent factors inﬂuencing stroke sequelae,
the disease pathophysiology remains largely unclear. Physical
steps of the ischemic event (such as the transient or
permanent interruption of the blood ﬂow and the focal or
global cerebral ischemia) are clearly pivotal determinants
for the disease prognosis. However, these aspects do not
explain some spatial heterogeneity in the cellular damage
that might directly reﬂect neuronal intrinsic susceptibility to
injury [4, 5]. Since cannabinoids might accumulate in the
ischemic brain [6, 7] and bind their receptors in neurons [8],
promising neuroprotective strategies targeting this system
to reduce the neuronal ischemic injury have been investi-
gated. On the other hand, since cannabinoids have been
shown to modulate brain resident microglial cells [9, 10],
cerebral blood vessels [11–14], and circulating inﬂammatory
cells [15, 16], a second therapeutic approach targeting2 Mediators of Inﬂammation
postischemic inﬂammation has been also explored. In the
following paragraphs, we will update scientiﬁc results on
the role of the cannabinoid receptors as potential regulators
of both nervous and immune systems after ischemic stroke
[9, 17, 18].
2.CannabinoidsandTheir Receptors
Endogenous cannabinoids (endocannabinoids) are chemi-
cally amides and esters of long polyunsaturated fatty acids
including arachidonoylethanolamide (anandamide [AEA])
and 2-arachidonoylglycerol (2-AG). AEA is a minor con-
stituent of the N-acylethanolamines (NAEs) family and
has been found elevated in serum and plaques of patients
with severe atherosclerotic diseases [19, 20]. On the other,
hand, 2-AG has been shown to reach higher concentrations
than anandamide analogues (such as palmitoylethanolamide
[PEA] and oleoylethanolamide [OEA]) in the brain and
atherosclerotic vessels [21]. Synthetic cannabinoids have
beenalsoinvestigatedinanimalmodelsshowinganimprove-
ment of the ischemic injury in the liver, heart, and brain
[22–24]. Furthermore, phytocannabinoids have been also
isolated from the Cannabis sativa. Since this plant contains
about 80 diﬀerent cannabinoids, a strong work is still
needed to test all these active compounds. This delay in
cannabinoid research might be also due to the very low
dose of certain cannabinoids in the plant. Thus, since
Δ9-tetrahydrocannabidiol (THC) and cannabidiol (CBD)
represent up to 40% of the total cannabinoid mass [25],
these compounds have been considered as the most active
mediators.
The eﬀects of cannabinoids are classically attributed to
the activation of the two major cannabinoids receptors (the
cannabinoid receptors type 1 [CB1] and type 2 [CB2]).
These transmembrane receptors are pivotal components of
the physiological endocannabinoid system together with
endogenous cannabinoids (endocannabinoids), their trans-
porters, and synthetic/degrading enzymes [26]. CB1 is highly
expressed in the brain [27–31]a sw e l la si nc a r d i o v a s c u l a r
tissues including the heart [32–34] and vascular vessels
[35–38]. Although it has been recently shown in the brain
[39, 40], CB2 is mainly expressed in the immune and
hematopoieticcells[10,41–43].Importantly,novelreceptors
capable of binding cannabinoids have been recently identi-
ﬁed. In particular, the transient receptor potential vanilloid
(TRPV) channels might be activated by cannabinoids [44–
46]. Among these channels, the activity and expression of
TRPV type 1, 3, and 4 could be modulated by classical
cannabinoids receptors agonists [41, 47–52]. On the other
hand, there is growing evidence that cannabinoids can acti-
vatetheperoxisomeproliferator-activatedreceptors(PPAR,a
family of nuclear receptors) in neurological diseases [53–57].
Although its activity has not been clariﬁed yet, the orphan
receptor GPR55 has been also identiﬁed to potentially bind
cannabinoids and intracellularly transduce their signals [58,
59].
3. Role of Cannabinoid Receptors in Poststroke
Inﬂammatory Injury
Some key events in the pathophysiology of ischemic stroke
include increased levels of inﬂammatory cytokines in the
brain, activation of microglia, and adhesion and migration
of peripheral leukocytes as a result of damage to the
blood-brain barrier [60]. A severe immunosuppression also
characterized by spleen atrophy has been described to follow
this initial inﬂammatory burst [61]. In order to inhibit the
acute inﬂammatory phase (strongly associated with cerebral
injury) [62], the treatment with Δ9-tetrahydrocannabinol
(THC, a cannabinoid receptor agonist) has been shown
to induce immunomodulatory properties in vitro [63–65].
Endocannabinoids (such as AEA and 2-AG) might be also
released by immune cells and neurons, thus locally modu-
lating immune response and cell diﬀerentiation within the
brain [66, 67]. Several immune cells (such as lymphocytes,
monocytes, and neutrophils, capable of inﬁltrating the
injured brain) have been shown to express on their surface
membrane both CB1 and CB2 receptors [41, 47, 68–71].
CB1 receptor is particularly expressed on T lymphocytes and
might be further upregulated by cannabinoid stimulation
[69, 72–75]. This mechanism might favor the paracrine
protective activity of AEA, which is highly produced in
the ischemic brain area and locally inhibits T lymphocyte
proliferation [76]. Importantly, CB1 expression has been also
conﬁrmed on cerebral macrophage-like cells, suggesting a
potential direct eﬀects of cannabinoids also on populations
resident in the brain [77]. On the other hand, the majority
of beneﬁcial eﬀects of cannabinoids is associated with CB2
receptor activation, which is classically described to inhibit
immune proinﬂammatory functions. CB2 receptor is also
expressed in immune organs (such as thymus and spleen)
[78] and circulating inﬂammatory cells (including T-, B-
lymphocytes, NK cells and monocytes and neutrophils) [79–
81]. Importantly, CB2 protein has been recently detected
in astrocytes [82], microglia [83], neural subpopulations,
and oligodendroglial progenitors [84], suggesting a potential
direct regulation of CB2 in cerebral poststroke inﬂammation
also in brain inﬂammatory cells [85]. The levels of CB2
receptor on microglial cells might depend on the cell
activation state in response to infection, inﬂammation and
stress [66, 86]. CB2 receptor is also upregulated in restricted
areasofthespinalcordinresponsetoperipheralnerveinjury
[87],suggestingthatneuronsandresidentinﬂammatorycells
might beneﬁt of cannabinoid treatments. Since CB1 and CB2
surface expression is upregulated during the inﬂammatory
activation [66, 88–90], treatment with cannabinoids might
be even more eﬀective in the early post-ischemic phase.
Treatment with the selective CB2 agonist JWH-133 was
shown to signiﬁcantly reduce microglial activation and
inﬂammatory gene expression (such as interleukin [IL]-
6, tumor necrosis factor [TNF]-α, regulated on activation,
normal T-cell expressed and secreted [RANTES], monocyte
chemoattractant protein [MCP]-1, and macrophage inﬂam-
matory peptide [MIP]-1α)i nam o u s em o d e lo fp e r m a n e n t
middle cerebral artery occlusion and focal cerebral ischemia
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was accompanied by the JWH-133-mediated improvement
of brain infarction and neurological “clinical” outcomes
[91]. Accordingly, pretreatment with CB2 agonists has
been shown to attenuate the poststroke enhancement of
leukocyte/endothelial cells interaction, adhesion molecule
expression, and disruption of blood-brain barrier (BBB)
[92–94]. In addition, CB2 knockout mice developed an
increased cerebral infarction, accompanied by worsened
neurological functions when compared to wild-type mice
[92].
Conﬁrming recent studies in other macrophage-medi-
ated inﬂammatory diseases (such as atherosclerosis and
rheumatoid arthritis) [15, 18, 95], these studies clearly show
that CB2 activation might actively reduce the post-stroke
cerebral microglial inﬂammation.
Cannabinoids might also aﬀect T lymphocyte function
and survival [65]. Although the role of T lymphocytes
in post-stroke inﬂammation has not been clariﬁed yet in
human beings [96, 97], recent evidence from mouse models
indicated that these cells might modulate their functional
capacities after an acute cerebral ischemia [61, 62, 98, 99].
In particular, the CD4+CD25+ regulatory T cells have been
suggested to play cerebroprotective activities in mice after a
focal cerebral ischemia [62, 98]. Therefore, the cannabinoid-
mediated beneﬁts might involve the T lymphocyte response.
In other inﬂammatory diseases, cannabinoid agonism has
been shown to aﬀect proliferation, polarization [66, 100],
and cytolytic capacity [101] of T cells. Recently, Tanikawa
and coworkers published that treatment with WIN-55,212-
2 favors the lymphocyte migration within the spleen, sup-
porting that this cannabinoid agonist directly downregulates
the immune response [102]. Accordingly, 2-AG strongly
reduces mitogen-induced proliferation of mouse splenocytes
[103]. These studies support a potential therapeutic role
of cannabinoid agonists to reduce T lymphocyte-mediated
inﬂammation in the post-stroke acute phase.
Although some eﬀort has been made in the past decades
to clarify the role of the cannabinoid system in post-
stroke inﬂammation, discrepancies deriving from the use of
diﬀerent types and doses of cannabinoids in both in vivo and
in vitro models still exist and represent a major limitation to
deﬁne clear conclusions.
4. The CannabinoidSystem in the Ischemic
Neuronal Injury
The acute reduction of blood ﬂow with the consequent
abrogation of oxygen and nutrient supply in the peripheral
cerebral tissue has been shown to signiﬁcantly modify
the neural electrolytic equilibrium and metabolism. The
cytosolic increase of reactive oxygen species (ROS), calcium,
and sodium has been described to directly increase neuron
necrosis and apoptosis in the early hours after the ischemic
onset [104]. Normally, the burst of ROS in the cytosol is
accompanied by a reduction in pH, while the release of
glutamate from the core of the infarcted area increases the
permanency of high intracellular calcium concentrations,
thus contributing to neuron injury. Deprivation of oxygen
and glucose during ischemia also contributes to the increase
in cytosolic Ca2+ via NMDA receptor-mediated pathways
[105]. Since drugs blocking Ca2+ channels have been shown
to protect cells, Ca2+ inﬂux is considered as pivotal patho-
physiological mechanism during an ischemic insult [106].
Together with the acute leukocyte inﬂux, these neuronal
modiﬁcations are probably the most relevant events in the
pathophysiologyofcerebralischemia/reperfusion[107,108].
Thus, cannabinoid-related mechanisms might serve as
promising candidates for the reduction of neuronal ischemic
injury. In particular, AEA and 2-AG have been shown
to especially accumulate in the brain ischemic areas [13,
109]. This enhancement occurs exponentially in a time-
dependent manner [110], suggesting a potential protective
role for endocannabinoids against the neuronal ischemic
injury. However, several discrepancies on the activation of
diﬀerent cannabinoid receptors in experimental models of
cerebral ischemia have to be clariﬁed. In particular, the
activation of CB1 receptor has been ﬁrstly indicated as
a neuroprotective strategy in transient cerebral ischemia
models [111]. On the other hand, Pegorini and coworkers
also showed that treatment with rimonabant (a selective CB1
antagonist but also a VR1 vanilloid receptor agonist) might
increase neuroprotection via the activation of this ligand-
gated cation channel [112]. These apparently paradoxical
results may ﬁnd an explanation in the diﬀerent aﬃnities
of cannabinoids for their receptors. In fact, depending on
the concentrations, cannabinoids might act as both agonists
and antagonists for certain receptors in the same time.
Importantly, an increase in CB2 receptor and TRPV1 and
a concomitant decrease in CB1 cerebral expression were
observed in mice underwent permanent middle cerebral
artery occlusion and intraperitoneally injected with leptin
[113]. The improvements of residual neurological disability
were associated with reduced infarct volume in brain,
suggesting that these receptors might beneﬁcially inﬂuence
the neuronal ischemic injury [113].
Taking into account these premises, the cannabinoid
receptors have been shown to activate deﬁned intracellu-
lar pathways in ischemic neurons [111, 114]. Speciﬁcally,
CB1 receptor activation triggers several protective signals
involving phosphorylation of mitogen-activated protein
kinase (MAPK) kinase 1/2 (MEK1/2), extracellular signal-
regulated kinase (ERK1/2), and nuclear factor-kappa B (NF-
κB) [114, 115]. These intracellular pathways might increase
neuronal survival. The ﬁrst-in-man study, investigating
the cannabinoid therapeutic approach on neuroprotection,
showed that the intravenous infusion of THC ameliorates
t h eg l o b a la n dr e g i o n a lc e r e b r a lb l o o dﬂ o wu pt o2 h
after the infusion of both low (0.15mg/min) and high
(0.25mg/min) doses [116]. The encouraging therapeutic
results of this study are in partial contrast with previous
case reports, suggesting a potential relationship between
stroke and chronic cannabis abuse in young human beings
[117–120]. Importantly, Mateo and coworkers recently
conﬁrmed the potential association between cannabis and
ischemic stroke recurrence in a young patient, without
identifying the underlying pathophysiological mechanisms
[121]. Evidence from autopsy examinations and imaging4 Mediators of Inﬂammation
reports in both human beings and animal models has
suggested that cannabis use might provoke cerebral stroke by
favouring the development of atrial ﬁbrillation, orthostatic
hypotension, and cerebral artery vasospasm [122–124]. In
a prospective study enrolling 48 young adults aﬀected
by ischemic stroke, Wolﬀ and co-workers also showed
that multifocal intracranial arterial stenosis was associated
with cannabis consumption in 21% [125]. Therefore, these
preliminary results in human beings suggest using caution
in the translational therapeutic approach of cannabinoid
from animal models. Further clinical studies (possibly using
more selective cannabinoid receptor agonist/antagonist) are
needed to clarify the potential therapeutic role of these
compounds against the ischemic stroke.
5. Conclusion
The endocannabinoid system is considered as a major
modulator of the cerebral blood ﬂow, neuroinﬂammation,
and neuronal survival. Despite of some controversies, the
activation of CB2 receptor has been shown to reduce cerebral
injury associated with acute post-stroke inﬂammation and
leukocyte inﬁltration. On the other hand, the direct role
of CB1 in neuronal protection has not been clariﬁed
yet. Evidence from animal models and in vitro studies
suggests a global protective role for cannabinoid recep-
tors agonists in ischemic stroke. However, further studies
are needed to clarify the role of the recently discovered
cannabinoid receptors (such as GPR55 or VR1 vanilloid
receptor) in the physiopathology of the infarcted brain
and related inﬂammation. At this regard, both synthetic
cannabinoids and endocannabinoids represent extremely
promising therapeutic compounds. Since human studies
are still missing, we cannot predict the potential clinical
beneﬁts of treatments targeting cannabinoid receptors in
ischemic stroke. We believe that the “cannabinoid” approach
represents an interesting therapeutic strategy still requiring
further validations to improve neurologic and inﬂammatory
outcomes in ischemic stroke.
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